Cidara Therapeutics Stock News

Cidara Therapeutics Inc. (NASDAQ:CDTX) price on Friday, November 19, fall -0.66% below its previous days close as a downside momentum from buyers pushed the stocks value to $1.50. A look at the stocks price movement, the close in the last trading session was $1.51, moving within a range at $1.452 and $1.525. The beta value Cidara Therapeutics Inc. (NASDAQ: CDTX) Fell -0.66%, Now What? Dont Panic Read More »

Cidara Therapeutics, Inc. (NASDAQ:CDTX) CEO Jeffrey Stein bought 50,000 shares of the stock in a transaction on Friday, November 12th. The shares were bought at an average price of $1.59 per share, for a total transaction of $79,500.00. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. []

Cidara Therapeutics (NASDAQ:CDTX) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued on Tuesday, Zacks.com reports. The brokerage currently has a $1.75 price target on the biotechnology companys stock. Zacks Investment Researchs price target suggests a potential upside of 4.17% from the companys previous close. []

Cidara Therapeutics, Inc. (NASDAQ:CDTX) CFO Preetam Shah acquired 20,000 shares of the firms stock in a transaction that occurred on Friday, November 12th. The stock was acquired at an average price of $1.54 per share, for a total transaction of $30,800.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which []

Cidara Therapeutics, Inc. (NASDAQ:CDTX) CFO Preetam Shah purchased 20,000 shares of Cidara Therapeutics stock in a transaction on Friday, November 12th. The stock was purchased at an average price of $1.54 per share, for a total transaction of $30,800.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is []

Related Stocks: CDTX ,

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 0.00% and 95.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients

SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for pati

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patient

Virtual event will highlight the broad potential of the Cloudbreak ® platform and the commercial potential for rezafungin

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 166.67% and 415.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patien

Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.